The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
People who took Zepbound lost 17 pounds more on average after 72 weeks of treatment than those who were given Novo Nordisk’s ...
Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, ...
That’s according to the latest data from real-time ad trackers iSpot.TV. Their analysts found AbbVie’s immunology drug duo ...
Eli Lilly said its weight loss drug Zepbound led to 47% greater weight reduction than rival medicine Wegovy, made by Novo ...
Novo Nordisk, the manufacturer of Ozempic and Wegovy, has petitioned the Food and Drug Administration (FDA) to add ...
Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.
Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S’s Wegovy in the first head-to-head ...
Novo Nordisk India team fears losing competitive edge to Eli Lilly Novo's Wegovy and Lilly's Mounjaro are GLP-1 receptor agonists India's obesity rates rising, increasing demand for weight-loss ...
Over the last two-plus years, as Eli Lilly and Novo Nordisk have battled for their share of the massive weight loss market ...
Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47 per cent more weight than those who were given ...